Skip to content
Peptide research

Triptorelin

Also known as Trelstar · Decapeptyl
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

A synthetic GnRH agonist that suppresses testosterone or estrogen to castrate levels after an initial hormone surge. Human evidence is strong: it is an established treatment for advanced prostate cancer, endometriosis, precocious puberty, and IVF ovarian suppression. Real risks include the initial tumor flare, meaningful bone density loss, hot flashes, and sexual dysfunction. It is an FDA-approved prescription drug, not a longevity or wellness product.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Effective androgen deprivation in advanced prostate cancer

    High

    FDA-approved; randomized trial showed non-inferiority to leuprolide, backed by Cochrane review.

  • Reduction of endometriotic lesions and pain symptoms

    High

    Placebo-controlled and post-surgical randomized trials show reduced pelvic pain and lesion severity.

  • Suppression of precocious puberty in children

    Medium

    Open-label pediatric trials show hormone suppression; no placebo-controlled study exists for ethical reasons.

Evidence limits

Evidence Level
Level 1 — FDA Approved

Triptorelin has one of the strongest evidence bases among peptide therapeutics, with Level I evidence across its primary indications. In prostate cancer, the EORTC 22961 trial (1,113 registered; 970 randomized; published in NEJM) is the cornerstone study demonstrating survival benefit for long-term ADT with triptorelin. This is supported by multiple Phase III trials demonstrating consistent testosterone suppression, a multicenter RCT confirming equivalence to surgical castration, and large-scale pharmacovigilance data from decades of post-marketing use. In endometriosis, the Bergqvist 1998 double-blind placebo-controlled RCT provides Level I evidence for lesion reduction and symptom control. In CPP, multiple Phase III trials and a meta-analysis support triptorelin's efficacy in achieving prepubertal hormone suppression. In IVF, triptorelin is an established standard-of-care agent for pituitary downregulation, supported by numerous RCTs. Safety is well-characterized through decades of clinical experience and FAERS pharmacovigilance analysis. Overall, triptorelin's evidence base is mature and robust — it is not an experimental peptide but a well-established pharmaceutical.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Undiagnosed vaginal bleeding

    Absolute

    Must rule out malignancy before starting GnRH agonist therapy.

  • Osteoporosis (severe)

    High

    Long-term use causes bone density loss through sex hormone suppression.

General cautions

  • Pregnancy

    Absolute

    FDA contraindication. Can cause fetal harm and spontaneous abortion.

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Tumor flare (initial hormone surge)

    High
  • Cardiovascular events (MI, stroke, sudden cardiac death)

    Moderate
  • QT prolongation and torsade de pointes

    Low
  • Bone mineral density loss and fracture risk

    High
  • Metabolic effects (hyperglycemia, diabetes, dyslipidemia)

    Moderate
  • Hot flashes and vasomotor symptoms

    High
  • Sexual dysfunction and loss of libido

    High
  • Seizures and neuropsychiatric effects

    Low
  • Pregnancy exposure (teratogenicity)

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.